Research programme: estrogen receptor ligands - ENDECE

Drug Profile

Research programme: estrogen receptor ligands - ENDECE

Alternative Names: NDC 1022; NDC 1308; NDC 1352; NDC 1407

Latest Information Update: 21 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ENDECE
  • Class Estradiol congeners; Small molecules
  • Mechanism of Action Apoptosis stimulants; Cell differentiation stimulants; Estrogen receptor agonists; Estrogen receptor alpha agonists; Estrogen receptor beta agonists; Estrogen receptor modulators; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple sclerosis

Highest Development Phases

  • Preclinical Alzheimer's disease; Multiple sclerosis
  • Research Neuropathic pain
  • No development reported Cancer; Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (IV)
  • 12 Jul 2016 ENDECE has patent protection for NDC 1308 in USA, Europe, Canada, Australia, China and Singapore
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top